Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2021 08:45 ET | Source: iBio, Inc.

Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202

- Global Reliance on Spike Protein-Based Vaccines May Create Public Health Risks - - Omicron’s Many Mutations Occur in Regions Outside Those of IBIO-202’s Nucleocapsid Antigen - - Company Expecting...
November 17, 2021 16:30 ET | Source: iBio, Inc.

Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting

BRYAN, Texas, Nov. 17, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
November 15, 2021 16:05 ET | Source: iBio, Inc.

iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update

- Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics - - Initiates Research Collaboration with UT Southwestern to Study Anti-fibrotics in Oncology - -...
November 15, 2021 13:00 ET | Source: iBio, Inc.

iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors

BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming...
November 08, 2021 16:30 ET | Source: iBio, Inc.

iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021

BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
November 03, 2021 16:47 ET | Source: iBio, Inc.

iBio Acquires FastPharming Manufacturing Facility®

- Takes Sole Ownership of CDMO Subsidiary & U.S. Manufacturing Rights - - Reduces Carrying Costs by Approximately 67% - BRYAN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
October 26, 2021 08:35 ET | Source: iBio, Inc.

iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9

BRYAN, Texas, Oct. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
September 27, 2021 07:30 ET | Source: iBio, Inc.

iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update

Expanded Immuno-Oncology Pipeline with License of Next-Gen anti-CD25 Antibody for Solid Tumors Paired Access to RubrYc’s Antibody Discovery Platform with FastPharming® and GlycaneeringTM...
September 20, 2021 16:30 ET | Source: iBio, Inc.

iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...
September 20, 2021 07:30 ET | Source: iBio, Inc.

iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based...